The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
 
Kimberly Perez
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene
 
Colin D. Weekes
Honoraria - Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; Merrimack; Merrimack; Merrimack; Merrimack
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Merrimack; Merrimack; Merrimack; Merrimack
Research Funding - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Halozyme; Halozyme; Halozyme; Halozyme; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Millennium; Millennium; Millennium; Millennium
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Merck; Merck; Merck; Merck; Tesaro; Tesaro; Tesaro; Tesaro
Travel, Accommodations, Expenses - Agios; Agios; Agios; Agios; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
Thomas Adam Abrams
Stock and Other Ownership Interests - Guardant Health; Guardant Health; Guardant Health; Guardant Health; InVitae; InVitae; InVitae; InVitae; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics
Consulting or Advisory Role - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis/Ipsen; Exelixis/Ipsen; Exelixis/Ipsen; Exelixis/Ipsen; Kaleido Biosciences; Kaleido Biosciences; Kaleido Biosciences; Kaleido Biosciences; Merck; Merck; Merck; Merck
Research Funding - Lilly; Lilly; Lilly; Lilly
Expert Testimony - Genentech; Genentech; Genentech; Genentech
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
 
Peter C. Enzinger
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; loxo; loxo; loxo; loxo; Merck; Merck; Merck; Merck; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Marios Giannakis
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Patents, Royalties, Other Intellectual Property - Patent pending on biomarkers of immune response; Patent pending on biomarkers of immune response; Patent pending on biomarkers of immune response; Patent pending on biomarkers of immune response
 
Lipika Goyal
Consulting or Advisory Role - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Cota Healthcare; Cota Healthcare; Cota Healthcare; Ignyta; Ignyta; Ignyta; Ignyta; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst)
 
Douglas Adam Rubinson
Consulting or Advisory Role - Augmenix; Augmenix; Augmenix; Augmenix
 
Matthew B. Yurgelun
No Relationships to Disclose
 
Danielle Stonely
No Relationships to Disclose
 
Srivatsan Raghavan
No Relationships to Disclose
 
Basil Bakir
No Relationships to Disclose
 
Koushik Das
No Relationships to Disclose
 
Jason Pitarresi
No Relationships to Disclose
 
Andrew Aguirre
No Relationships to Disclose
 
Michael N. Needle
Employment - AVEO; AVEO; AVEO; AVEO
Leadership - AVEO; AVEO; AVEO; AVEO
Stock and Other Ownership Interests - AVEO; AVEO; AVEO; AVEO
 
Anil Rustgi
No Relationships to Disclose
 
Brian M. Wolpin
Honoraria - Celgene; Celgene; Celgene; Celgene; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; BioLineRx; BioLineRx; BioLineRx; Celgene; Celgene; Celgene; Celgene; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Genentech; Genentech; Genentech; Genentech; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL; GRAIL
Research Funding - Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly